[go: up one dir, main page]

DE69825626D1 - Heterozyklische cytotoxische wirkstoffe - Google Patents

Heterozyklische cytotoxische wirkstoffe

Info

Publication number
DE69825626D1
DE69825626D1 DE69825626T DE69825626T DE69825626D1 DE 69825626 D1 DE69825626 D1 DE 69825626D1 DE 69825626 T DE69825626 T DE 69825626T DE 69825626 T DE69825626 T DE 69825626T DE 69825626 D1 DE69825626 D1 DE 69825626D1
Authority
DE
Germany
Prior art keywords
heterocyclic
active substances
cytotoxic active
present
cytotoxic
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Lifetime
Application number
DE69825626T
Other languages
English (en)
Inventor
J Lavoie
B Makhey
Baoping Zhao
Fong Liu
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Rutgers State University of New Jersey
Original Assignee
Rutgers State University of New Jersey
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Rutgers State University of New Jersey filed Critical Rutgers State University of New Jersey
Application granted granted Critical
Publication of DE69825626D1 publication Critical patent/DE69825626D1/de
Anticipated expiration legal-status Critical
Expired - Lifetime legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D491/00—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00
    • C07D491/02—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00 in which the condensed system contains two hetero rings
    • C07D491/04—Ortho-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D221/00—Heterocyclic compounds containing six-membered rings having one nitrogen atom as the only ring hetero atom, not provided for by groups C07D211/00 - C07D219/00
    • C07D221/02—Heterocyclic compounds containing six-membered rings having one nitrogen atom as the only ring hetero atom, not provided for by groups C07D211/00 - C07D219/00 condensed with carbocyclic rings or ring systems
    • C07D221/04—Ortho- or peri-condensed ring systems
    • C07D221/18—Ring systems of four or more rings

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
  • Other In-Based Heterocyclic Compounds (AREA)
DE69825626T 1997-12-12 1998-12-11 Heterozyklische cytotoxische wirkstoffe Expired - Lifetime DE69825626D1 (de)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US08/989,576 US6140328A (en) 1997-12-12 1997-12-12 Heterocyclic cytotoxic agents
PCT/US1998/026292 WO1999031067A1 (en) 1997-12-12 1998-12-11 Heterocyclic cytotoxic agents

Publications (1)

Publication Number Publication Date
DE69825626D1 true DE69825626D1 (de) 2004-09-16

Family

ID=25535240

Family Applications (1)

Application Number Title Priority Date Filing Date
DE69825626T Expired - Lifetime DE69825626D1 (de) 1997-12-12 1998-12-11 Heterozyklische cytotoxische wirkstoffe

Country Status (12)

Country Link
US (2) US6140328A (de)
EP (1) EP1042294B1 (de)
JP (1) JP2002508359A (de)
CN (1) CN1286685A (de)
AT (1) ATE273281T1 (de)
AU (1) AU748624B2 (de)
CA (1) CA2313797A1 (de)
CZ (1) CZ20002176A3 (de)
DE (1) DE69825626D1 (de)
IL (1) IL136558A0 (de)
PL (1) PL341050A1 (de)
WO (1) WO1999031067A1 (de)

Families Citing this family (19)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6140328A (en) * 1997-12-12 2000-10-31 Rutgers, The State University Of New Jersey Heterocyclic cytotoxic agents
US6833373B1 (en) 1998-12-23 2004-12-21 G.D. Searle & Co. Method of using an integrin antagonist and one or more antineoplastic agents as a combination therapy in the treatment of neoplasia
US6858598B1 (en) 1998-12-23 2005-02-22 G. D. Searle & Co. Method of using a matrix metalloproteinase inhibitor and one or more antineoplastic agents as a combination therapy in the treatment of neoplasia
US6740650B2 (en) * 1999-10-29 2004-05-25 Rutgers, The State University Of New Jersey Heterocyclic cytotoxic agents
ATE405568T1 (de) * 2001-11-14 2008-09-15 Univ Rutgers Cytotoxische mittel
DE60235287D1 (de) * 2001-11-14 2010-03-25 Univ Rutgers Löslich gemachte topoisomerase-gifte
DE60231426D1 (de) * 2001-11-14 2009-04-16 Univ Rutgers Solubilisierte topoisomerase-gift-mittel
EP1453506B1 (de) * 2001-11-14 2008-04-02 Rutgers, The State University Topoisomerase-giftmittel
AU2003268075A1 (en) * 2002-08-09 2004-02-25 Edmond J. Lavoie Nitro and amino substituted dibenzonaphthyridines as topoisomerase agents
US6992088B2 (en) * 2002-08-09 2006-01-31 Rutgers, The State University Of New Jersey Nitro and amino substituted heterocycles as topoisomerase I targeting agents
WO2004014918A1 (en) * 2002-08-09 2004-02-19 Rutgers, The State University Nitro and amino substituted topoisomerase agents
AU2003290818A1 (en) * 2002-11-12 2004-06-03 Edmond J. Lavoie Topoisomerase-targeting agents
MX369262B (es) 2005-02-16 2019-11-04 Anacor Pharmaceuticals Inc Moleculas pequeñas que contienen boro.
WO2007078340A2 (en) * 2005-12-30 2007-07-12 Anacor Pharmaceuticals, Inc. Boron-containing small molecules
CN102532180B (zh) * 2005-12-30 2016-06-29 安纳考尔医药公司 含硼的小分子
TW201038578A (en) 2009-01-30 2010-11-01 Univ Rutgers Methods to treat cancer
ES2401563T3 (es) * 2009-03-06 2013-04-22 Rutgers, The State University Of New Jersey Derivados de metilendioxibenzo [I]fenantridina usados para tratar el cáncer
WO2010127363A1 (en) 2009-05-01 2010-11-04 Rutgers, The State University Of New Jersey Toposiomerase inhibitors
CA3019945A1 (en) 2016-04-04 2017-10-12 Rutgers, The State University Of New Jersey Topoisomerase poisons

Family Cites Families (18)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
USRE26065E (en) 1966-07-19 Folybenzimidazoles and their preparation
US26065A (en) * 1859-11-08 Improvement in cotton-gins
US2985661A (en) * 1956-02-06 1961-05-23 American Cyanamid Co Preparation of 2(omicron-aminophenyl)-benzimidazole
CH420045A (de) * 1964-09-01 1967-03-15 Ciba Geigy Verwendung von neuen Poly-azolen als optische Aufhellmittel für textile organische Materialien
DE1670684A1 (de) * 1966-04-01 1970-12-03 Hoechst Ag Verfahren zur Herstellung von basisch substituierten Bis-benzimidazol-derivaten
US3912740A (en) * 1974-02-28 1975-10-14 Us Health Method for the preparation of oxygenated benzo{8 c{9 phenanthridine compounds
PT73763B (fr) * 1981-10-01 1983-10-26 Quatrum Empresa Nacional De Qu Procede pour la preparation de nouveaux epoxides d'alkaloides benzofenantridiniques et de compositions pharmaceutiques qui les contiennent
US4749708A (en) 1982-05-14 1988-06-07 Maroko Peter R Composition for improving circulatory performance
US5153178A (en) 1982-05-14 1992-10-06 Maroko Peter R Compositions and method of treatment for improving circulatory performance
US4761417A (en) 1982-05-14 1988-08-02 Maroko Peter R Compounds, compositions and method of treatments for improving circulatory performance
US5244903A (en) * 1987-03-31 1993-09-14 Research Triangle Institute Camptothecin analogs as potent inhibitors of topoisomerase I
JP2700475B2 (ja) * 1988-07-30 1998-01-21 コニカ株式会社 非線形光学材料および非線形光学素子
US4938949A (en) * 1988-09-12 1990-07-03 University Of New York Treatment of damaged bone marrow and dosage units therefor
US5106863A (en) * 1990-03-26 1992-04-21 Ortho Pharmaceutical Corporation Substituted imidazole and pyridine derivatives
US5126351A (en) * 1991-01-24 1992-06-30 Glaxo Inc. Antitumor compounds
US5223506A (en) * 1991-06-04 1993-06-29 Glaxo Inc. Cyclic antitumor compounds
CZ254498A3 (cs) * 1996-02-12 1998-12-16 Rutgers, The State University Of New Jersey Analogy coralynu jako inhibitory topoisomerasy
US6140328A (en) * 1997-12-12 2000-10-31 Rutgers, The State University Of New Jersey Heterocyclic cytotoxic agents

Also Published As

Publication number Publication date
AU1909199A (en) 1999-07-05
AU748624B2 (en) 2002-06-06
WO1999031067A1 (en) 1999-06-24
EP1042294B1 (de) 2004-08-11
ATE273281T1 (de) 2004-08-15
CA2313797A1 (en) 1999-06-24
US6140328A (en) 2000-10-31
JP2002508359A (ja) 2002-03-19
EP1042294A1 (de) 2000-10-11
IL136558A0 (en) 2001-06-14
CZ20002176A3 (cs) 2001-11-14
PL341050A1 (en) 2001-03-26
US6486167B1 (en) 2002-11-26
CN1286685A (zh) 2001-03-07

Similar Documents

Publication Publication Date Title
DE69825626D1 (de) Heterozyklische cytotoxische wirkstoffe
TR199900920T2 (xx) Nafthiridin t�revleri.
TR200200749T2 (tr) Kinazolin bileşikleri ve bunları içeren farmasötik bileşikler.
AR029383A1 (es) Moleculas pequenas, los intermediarios para su sintesis, las composiciones farmaceuticas que las contienen y su uso para preparar un medicamento destinado al tratamiento o la profilaxis de enfermedades inflamatorias o mediadas por celulas inmunes
GEP20043241B (en) Compounds for Treatment of Ischemia and Pharmaceutical Compositions Containing the Same
PT1161428E (pt) Compostos de pirimidina
MX9702382A (es) Nuevos derivados de pirimidona con actividad antifungica.
PT839154E (pt) Peptidos e composicoes biologicamente activos sua utilizacao
SE9504661D0 (sv) New compounds
TR200100075T2 (tr) 2-Kuinolon ihtiva eden farmasötik bileşimler
DE60038183D1 (de) Verbindungen und zusammensetzungen zur abgabe aktiver wirkstoffe
UY25679A1 (es) Derivados de quinolin-2-ona inhibidores de la farnesil proteína transferasa útiles como agentes contra el cáncer
TR200200717T2 (tr) Terapötik kinazolin türevleri.
DK1093819T3 (da) Forbindelse og præparat til tilförsel af aktive midler
EE200200148A (et) Kinasoliini derivaadid, nende valmistamise meetodning kasutamine
TR199901765T2 (xx) S�lfomid-metalloproteaz inhibit�rleri
IL127965A0 (en) Pentafluorobenzenesulfonamide derivatives analogs thereof and pharmaceutical compositions containing the same
RU94036448A (ru) Производные галантамина и фармацевтическая композиция
DE69924292D1 (de) Pyrazol verbindungen und ihre verwendung
IL136359A0 (en) Dihydrobenzofuran derivatives and pharmaceutical compositions containing the same
SE0203070D0 (en) Novel compounds
SE0003476D0 (sv) Compounds
BG104717A (en) Water soluble azoles as broad-spectrum antifungals
ATE171943T1 (de) Piperidin-verbindungen, ihre darstellung und ihre verwendung
EP1109560A4 (de) Als inhibitoren der aicarftnützliche verbindungen

Legal Events

Date Code Title Description
8332 No legal effect for de